Business Wire

TX-PLANVIEW

10.5.2021 15:02:12 CEST | Business Wire | Press release

Share
Planview Names Razat Gaurav as Chief Executive Officer

Planview, a global leader in Portfolio Management and Work Management, today announced the appointment of Razat Gaurav as Chief Executive Officer, effective immediately. Gaurav, who is also joining the Company’s Board of Directors, succeeds Greg Gilmore, who is retiring and will continue to serve on the Board of Directors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005500/en/

With more than 20 years of experience in the enterprise software space, Gaurav brings proven leadership in scaling and growing businesses on a global basis. Most recently, Gaurav served as CEO of LLamasoft, where he was instrumental in driving an expanded product vision for AI based supply chain design and decision making. This vision, combined with a purpose-driven culture, enabled the company to more than double its revenue in three years and resulted in a successful $1.5 billion acquisition by Coupa in November 2020. Earlier in his career, Gaurav held leadership positions at Blue Yonder, i2 Technologies, and Ernst & Young’s management consulting practice. He also served on the Board of Directors of Sparta Systems (since acquired by Honeywell) and LLamasoft.

“Enterprises today are grappling with massive change and a surge in digital transformation initiatives – and the way teams work to turn strategy into outcomes has to evolve,” said Gaurav. “Planview has a rich history of technology innovation and industry leadership, as well as a proven track record of partnering with customers to transform their enterprises to meet the demands of our changing environment. I’m pleased to join Planview at an exciting time in the company’s growth trajectory and look forward to working with the team to reimagine the future of digital transformation in the enterprise.”

Gaurav’s appointment marks the next step for Planview as it looks to further accelerate its growth. Most recently, Planview acquired Clarizen and Changepoint , advancing the Company’s leadership in Portfolio Management and Work Management, and creating an unmatched community of Agile leaders, PMOs, PPM, and Professional Services Automation (PSA) practitioners. In December 2020, the company was acquired by private equity firms TPG and TA Associates for $1.6 billion .

“I have had the privilege of knowing Razat for several years and have seen firsthand his ability to build technology businesses that create differentiated value for their customers. His track record of driving growth through innovation and company culture makes him a perfect fit for Planview,” said Nehal Raj, Partner at TPG Capital. On behalf of the Board, I want to thank Greg for his leadership and stewardship of Planview for more than 25 years. We wish him the best in his retirement and appreciate his continued service on the board.”

“Under Greg's leadership, Planview has established itself as an industry leader and trusted partner to its customers,” said Ashu Agrawal, a Managing Director at TA Associates. “Looking ahead, we are confident that Razat brings the ideal combination of digital transformation expertise and experience successfully scaling enterprise software businesses to lead Planview through its next chapter. We’re pleased to welcome him aboard.”

“It has been an honor and a privilege to help lead Planview for the last 25 years, and to work alongside such extraordinary colleagues, customers, and partners,” said Gilmore. “I’m proud of the accomplishments and results we have delivered as a company, and believe that Planview is well positioned for exceptional success in the years to come.”

About Planview

Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions enable organizations to navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 1,000 employees supporting 4,500 customers and 1.3 million users worldwide. For more information, visit: www.planview.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye